OliX Pharmaceuticals is joining hands with the French bio corporations "VECT-Horus" to verify delivery technology for short interfering RNA (siRNA) therapies for central nervous system (CNS) diseases.
OliX Pharmaceuticals said on the 4th that it signed a material transfer and evaluation agreement (MTEA) with VECT-Horus and will jointly evaluate CNS delivery efficacy by combining VECT-Horus' blood-brain barrier (BBB) shuttle platform "Vectrans" with its own siRNA conjugates.
The two sides plan to comprehensively analyze delivery efficiency to CNS tissues, target gene expression inhibition, and biodistribution in major organs through this collaboration. Through this, they aim to verify early the feasibility of developing siRNA-based CNS therapeutics and lay the groundwork for future strategic discussions and expanded cooperation.
Vectrans has already proven its technology by signing global exclusive license agreements with global pharmaceutical companies such as Novo Nordisk, Ionis, and Radiomedix. OliX Pharmaceuticals expects that by integrating Vectrans into its high-efficiency siRNA platform, it can secure differentiated competitiveness in CNS disease areas that have been difficult to reach with existing treatments.
Vectrans has been recognized for its technology through global exclusive license agreements with global corporations such as Novo Nordisk, Ionis, and Radiomedix. OliX Pharmaceuticals expects that by combining its high-efficiency siRNA platform with Vectrans, it can secure a differentiated competitive edge in CNS disease areas that have been difficult to access with existing treatment methods.
Lee Dong-gi of OliX Pharmaceuticals said, "This collaboration is an important turning point in advancing from an siRNA single-technology corporations to a platform corporations with global pipeline competitiveness through delivery technology and indication expansion," and added, "By proactively introducing and evaluating a validated BBB shuttle, we are targeting both the potential for technology transfer and a long-term rise in corporate value in the CNS therapeutics field."